nutrafoods-international-journal-logo-80nutrafoods-international-journal-logo-80nutrafoods-international-journal-logo-80nutrafoods-international-journal-logo-80
  • HOME
  • NUTRAFOODS BOARD
  • ARTICLES
  • SUBMIT A MANUSCRIPT
  • CHECK STATUS

Human milk oligosaccharides and antibiotics: a valuable combination to control infectious diseases

Infectious diseases remain a major health challenge and are becoming increasingly difficult to manage due to the spread of antibiotic resistance. A novel approach is to exploit human milk oligosaccharides (HMOs), which are now known to reduce the prevalence of infectious diseases among breastfed infants. HMOs have bacteriostatic or bactericidal activity against a wide range of important pathogens, such as Streptococcus agalactiae (group B Streptococcus), Streptococcus pneumoniae, Campylobacter jejuni, Clostridioides difficile, Entamoeba histolytica and Candida albicans. Furthermore, HMOs can act synergistically with antibiotics, reducing the minimum inhibitory concentration for certain antibiotics by up to 32-fold. This could extend the therapeutic window of some antibiotics and also reduce the doses required to treat infectious diseases. Given the risk posed by the emergence of antibiotic-resistant pathogens, it would be advantageous to further exploit this synergism between antibiotics and HMOs.

DOI: 10.17470/NF-020-0026

DATE: 2020

AUTHOR/S: Adams C, Gutiérrez B

ABSTRACT:
Infectious diseases remain a major health challenge and are becoming increasingly difficult to manage due to the spread of antibiotic resistance. A novel approach is to exploit human milk oligosaccharides (HMOs), which are now known to reduce the prevalence of infectious diseases among breastfed infants. HMOs have bacteriostatic or bactericidal activity against a wide range of important pathogens, such as Streptococcus agalactiae (group B Streptococcus), Streptococcus pneumoniae, Campylobacter jejuni, Clostridioides difficile, Entamoeba histolytica and Candida albicans. Furthermore, HMOs can act synergistically with antibiotics, reducing the minimum inhibitory concentration for certain antibiotics by up to 32-fold. This could extend the therapeutic window of some antibiotics and also reduce the doses required to treat infectious diseases. Given the risk posed by the emergence of antibiotic-resistant pathogens, it would be advantageous to further exploit this synergism between antibiotics and HMOs.

KEYWORDS:
Antibiotic resistance, pathogen control, dose rate, synergism

 

DOI 10.17470/NF-020-0026

Download Article

Find a Specific Article

Find by Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016


ISSN 2240-5291 (electronic edition)

EDITORIAL INFORMATION

Editor-in-Chief
Francesco Di Pierro

Journal Office
Anna Lebovich

Mail: info@nutrafoods.eu

Copyright 2019 – Nutrafoods.eu

International Journal on Nutraceuticals, Functional Foods and Novel Foods
- from Research to Industrial Applications -


Privacy Policy  |  Cookies Policy
WebMaster KosmoSol
 
      By continuing to browse the site you are agreeing to our use of cookies.